RPT Labworks Secures Angel Investment from STAN to Accelerate Radiopharmaceutical Development
RPT Labworks, a Madison, Wisconsin–based contract research organization that provides end‑to‑end preclinical radiopharmaceutical theranostics development and testing services, has secured investment support from the Science & Technology Angels Network (STAN) as part of its growth strategy to accelerate its scientific and operational capabilities.
Founded by radiopharmaceutical experts Justin Jeffery and Reinier Hernandez, RPT Labworks operates a state‑of‑the-art laboratory that assists pharmaceutical, biotech, and academic partners with radiochemistry, in vitro and in vivo studies, imaging, dosimetry and preclinical IND package support — services critical to advancing novel targeted cancer therapies from discovery toward clinical translation.
The angel investment from STAN, a global network of angel investors focused on early‑stage science and technology ventures, underscores growing investor interest in the radiopharmaceutical sector, where precision oncology and molecular imaging technologies are rapidly gaining traction. This strategic backing is designed to help RPT Labworks expand its operational footprint and support a broader portfolio of preclinical programs that bridge scientific discovery with patient impact, particularly in the underserved field of targeted radionuclide drug development.
STAN’s support comes amid broader momentum in life sciences and biotechnology investment, where specialized contract research organizations are essential partners to innovators working on next‑generation diagnostics and therapeutics. RPT Labworks’ integrated service offerings — from method development and radiolabeling to comprehensive toxicology and biodistribution analyses — enable clients to de‑risk early‑stage programs and streamline paths to clinical readiness.
The investment is part of RPT Labworks’ ongoing efforts to strengthen its scientific infrastructure, enhance research throughput, and scale capabilities that meet the evolving needs of pharmaceutical and biotech partners. With expertise spanning multiple radionuclides used for both imaging and therapeutic applications, the company is positioned to support a wide range of radiopharmaceutical modalities that are increasingly sought after in precision oncology research.
“This investment from STAN reflects confidence in our vision to accelerate radiopharmaceutical discovery and bring life‑saving therapies to patients faster,” said a spokesperson for RPT Labworks. The company’s mission emphasizes the importance of rigorous scientific methodology coupled with agile execution, enabling accurate, reproducible results that accelerate partner programs toward clinical translation.
Radiopharmaceuticals — which combine radioactive isotopes with targeting molecules to diagnose or treat disease at the cellular level — represent one of the most promising frontiers in precision oncology. As demand for these targeted therapies grows, so does the need for expert preclinical partners like RPT Labworks that can deliver comprehensive development services under one roof.
The support from STAN is expected to help RPT Labworks invest in key areas such as scientific staffing, infrastructure enhancements, and expanded service lines that strengthen its position as a premier radiopharmaceutical CRO. Additionally, the capital and strategic guidance from a global angel network are anticipated to amplify the company’s visibility within the biotech ecosystem, potentially attracting further collaborations and partnerships with pharmaceutical and biotech innovators worldwide.
RPT Labworks’ leadership team brings decades of experience in nuclear medicine, molecular imaging and cancer biology, and the company’s facilities are situated within Madison’s dynamic personalized medicine and biotech innovation ecosystem. This environment supports synergistic relationships with academic institutions, isotope suppliers and other research organizations, further enhancing RPT Labworks’ ability to contribute to the advancement of targeted therapies.
In the context of increasing interest in radiopharmaceuticals by both biotech investors and therapeutic developers, RPT Labworks’ recent investment from STAN positions the company to play a pivotal role in enabling next‑generation cancer diagnostics and treatments. The company continues to refine its scientific platforms and expand its research capabilities, aligning with broader industry trends that emphasize precision, speed and translational rigor in drug development.
With this infusion of angel support, RPT Labworks is poised to enhance its contribution to the radiopharmaceutical research landscape, helping partners accelerate promising radiotherapeutic and imaging agents from the lab bench closer to clinical benefit for patients worldwide.
